Regulus Therapeutics Reports First Quarter 2021 Financial Results and Recent Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/9/2026
- Wall St futures rebound as oil retreats, investors weigh US-Iran tensions
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Oil prices fall as markets weigh impact of US strikes on Iran
- Nvidia is up just 3% YTD while SOX surges 82% — what’s holding it back?
- BofA says S&P 500 technicals point to corrective Q3
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- GameStop stockholders approve share count increase to 2.5 billion
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- AI bubble fears mount as Zuckerberg admits agent delays and Burry shorts sector
- S&P 500 ends down after Trump says Iran deal is 'over'
Regulus Therapeutics (RGLS) Tops Q1 EPS by 1c
May 13, 2021 4:24 PM EDTRegulus Therapeutics (NASDAQ: RGLS) reported Q1 EPS of ($0.08), $0.01 better than the analyst estimate of ($0.09).
"We are excited about the data we recently announced from the first cohort of our phase 1b clinical trial of RGLS4326 for the treatment of patients with ADPKD... More
